Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting

Stephen V. Liu, MD
Zofia Piotrowska, MD, MHS
Released: September 25, 2020

Conclusions

Stephen V. Liu, MD
We saw exciting advances in NSCLC for many molecularly defined patient subgroups at ASCO 2020, but as Dr. Piotrowska mentioned, these studies will only have an impact if we successfully identify the patients who will benefit from these targeted agents. So, I would say an important take-home lesson is that we need to embrace broad molecular profiling by next-generation sequencing to get the right drugs to the right patients, potentially as early as the resectable setting (per ADAURA).

Zofia Piotrowska, MD, MHS
I agree. It is so exciting to see new and effective targeted therapy options for patients with NSCLC coupled with a broader use of existing targeted therapies, such as in the ADAURA and ADJUVANT-CTONG 1104 trials that evaluated EGFR TKIs as adjuvant therapy in the early-stage setting. But again, testing will be critical to get these new and exciting therapies to the patients who will benefit from them. There were also intriguing results in the immunotherapy space, including promising data on the novel TIGIT antibody tiragolumab. After years of improvements with known drugs and regimens, it’s hopeful to see new agents being developed, because there is still room for improvement in the treatment of lung cancer.

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings